Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy

Dhanesh Amarnani, Arturo Israel Machuca-Parra, Lindsay L Wong, Christina K Marko, James A Stefater, Tomasz P Stryjewski, Dean Eliott, Joseph F Arboleda-Velasquez, Leo A Kim, Dhanesh Amarnani, Arturo Israel Machuca-Parra, Lindsay L Wong, Christina K Marko, James A Stefater, Tomasz P Stryjewski, Dean Eliott, Joseph F Arboleda-Velasquez, Leo A Kim

Abstract

Purpose: The purpose of this study was to develop a method for isolating, culturing, and characterizing cells from patient-derived membranes in proliferative vitreoretinopathy (PVR) to be used for drug testing.

Methods: PVR membranes were obtained from six patients with grade C PVR. Membrane fragments were analyzed by gross evaluation, fixed for immunohistologic studies to establish cell identity, or digested with collagenase II to obtain single cell suspensions for culture. PVR-derived primary cultures were used to examine the effects of methotrexate (MTX) on proliferation, migration, and cell death.

Results: Gross analysis of PVR membranes showed presence of pigmented cells, indicative of retinal pigment epithelial cells. Immunohistochemistry identified cells expressing α-smooth muscle actin, glial fibrillary acidic protein, Bestrophin-1, and F4/80, suggesting the presence of multiple cell types in PVR. Robust PVR primary cultures (C-PVR) were successfully obtained from human membranes, and these cells retained the expression of cell identity markers in culture. C-PVR cultures formed membranes and band-like structures in culture reminiscent of the human condition. MTX significantly reduced the proliferation and band formation of C-PVR, whereas it had no significant effect on cell migration. MTX also induced regulated cell death within C-PVR as assessed by increased expression of caspase-3/7.

Conclusions: PVR cells obtained from human membranes can be successfully isolated, cultured, and profiled in vitro. Using these primary cultures, we identified MTX as capable of significantly reducing growth and inducing cell death of PVR cells in vitro.

Figures

Figure 1
Figure 1
Culture of human PVR membranes and histopathology of PVR membranes. (A) Fundus photograph of the left eye of a patient, case 6 (PVR-06) with recurrent retinal detachment; note presence of a gas bubble within the eye from previous retinal surgery. There is a band of pigmented PVR along the inferior arcade (outlined by white lines). Also note inferior retinal holes in area of detached retina (white arrows). (B) Phase contrast view of the PVR membrane after surgical excision from PVR-06. Scale bar denotes 500 μm. (C) C-PVR cells from case 3 (PVR-03) after 1 week in culture. (D) After 4 weeks in culture, note the formation of bands between the membrane and the rim of the culture dish. (E) C-PVR cells from case 5 (PVR-05) were similarly confluent after 1 week. (F) After 4 weeks in culture, cells grew on top of each other with loss of cell contact inhibition. Scale bar denotes 100 μm. (G–U) Light micrographs of PVR membranes from three different cases (PVR-02, PVR-03, and PVR-05) using primary antibodies (all in red) against SMA (G–I), GFAP (J–L), CD14 (M–O), BEST-1 (P–R), cytokeratin (S–U), and counterstained with hematoxylin (blue). Scale bar denotes 100 μm.
Figure 2
Figure 2
Characterization of cultured cells by immunofluorescence. Immunofluorescence of C-PVR cells from four different cases using primary antibodies against (A–D) SMA all in green, (E–H) GFAP all in red, (I–L) cytokeratin (intermediate filaments in epithelial cells) all in green, and (M–P) F4/80 (immune cells) all in red and counterstained with DAPI (blue). Scale bar denotes 100 μm.
Figure 3
Figure 3
Expression of cell identity molecular markers in PVR membranes is retained in C-PVR primary cultures. (A) Specific populations of C-PVR cells contained pigmented granules (white arrows), characteristic of RPE cells. These granules were released from the cells after 48 to 72 hours. Scale bar denotes 500 μm. (B) C-PVR cells grew as a confluent monolayer in growth medium containing EBM-2 supplemented with SingleQuots Kit (Lonza) and 12% FBS. Scale bar denotes 100 μm. (C) A transformation from a monolayer to invasive cell clusters was triggered by switching to a differentiation culture medium. The phenotypic change was reversible by switching back to the growth medium. Scale bar denotes 500 μm. (D) PVR membrane from clinical case 3 was processed for immunohistochemistry using the antibody against SMA in red and counterstained with hematoxylin (blue). Scale bar denotes 100 μm. (E) Immunofluorescence of the C-PVR primary cultures showing positive cells for SMA in green, suggesting that this molecular marker is retained in C-PVR primary cultures. Nuclei are counterstained with DAPI. Scale bar denotes 100 μm. (F) Cell cluster shown in (C) was harvested and processed for immunocytochemistry using antibody against SMA. Scale bar denotes 100 μm.
Figure 4
Figure 4
Effect of MTX on cell density and band formation of C-PVR. Phase contrast and Hoechst-stained immunofluorescence images of C-PVR cells from PVR-03 after 6 weeks of culture without MTX (A–C) and with 100 (D–F), 200 (G–I), and 400 μM (J–L) MTX. (M) Graph shows quantification of cell density after treatment with different concentrations of MTX or control. Error bars represent SEM. Scale bar denotes 100 μm.
Figure 5
Figure 5
Effect of MTX on proliferation of C-PVR cells. Immunofluorescence images of C-PVR cells from after 24, 48, and 72 hours without (A, E, I) and with 100 (B, F, J), 200 (C, G, K), and 400 mM (D, H, L) MTX. Quantification of proliferation by Ki67 immunofluorescence (red) at 24, 48, and 72 hours (M–O, respectively). Error bars represent SEM. Scale bar denotes 100 μm.
Figure 6
Figure 6
Effect of MTX on C-PVR survival. Hoechst-stained immunofluorescence images of C-PVR cells from PVR-05 after 6 weeks of culture without MTX (A–C) and with 100 (D–F), 200 (G–I), and 400 μM (J–L) MTX. (M) Quantification of cell density showing a significant reduction in cell density after 2, 4, and 6 weeks under the treatment with MTX. (N) Quantification of apoptosis showing a significant increase in the presence of Caspases 3 and 7 after different time points (2, 4, and 6 weeks) with MTX. Error bars represent SEM. Scale bar denotes 100 μm.

References

    1. Weichel ED, Colyer MH. . Combat ocular trauma and systemic injury. Curr Opin Ophthalmol. 2008; 19: 519– 525.
    1. Colyer MH, Chun DW, Bower KS, Dick JS, Weichel ED. . Perforating globe injuries during operation Iraqi Freedom. Ophthalmology. 2008; 115: 2087– 2093.
    1. Eliott D, Stryjewski TP, Andreoli MT, Andreoli CM. . Smoking is a risk factor for proliferative vitreoretinopathy after traumatic retinal detachment. Retina. 2017; 37: 1229– 1235.
    1. Martini B. . Proliferative vitreo-retinal disorders: experimental models in vivo and in vitro. Acta Ophthalmol Suppl. 1992; 201: 1– 63.
    1. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983; 90: 121– 125.
    1. Ryan SJ. . Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 1993; 115: 1– 20.
    1. Khan MA, Brady CJ, Kaiser RS. . Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015; 35: 165– 175.
    1. Hsu J, Khan MA, Shieh WS,et al. . Effect of serial intrasilicone oil bevacizumab injections in eyes with recurrent proliferative vitreoretinopathy retinal detachment. Am J Ophthalmol. 2016; 161: 65– 70.
    1. Cheema RA, Peyman GA, Fang T, Jones A, Lukaris AD, Lim K. . Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging. 2007; 38: 365– 370.
    1. Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. . Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology. 2008; 115: 1938– 1943.
    1. Munir WM, Pulido JS, Sharma MC, Buerk BM. . Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005; 40: 598– 604.
    1. Reibaldi M, Russo A, Longo A,et al. . Rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol. 2013; 4: 79– 83.
    1. Blumenkranz M, Hernandez E, Ophir A, Norton EW. . 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. 1984; 91: 122– 130.
    1. Asaria RH, Kon CH, Bunce C,et al. . Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001; 108: 1179– 1183.
    1. Charteris DG, Aylward GW, Wong D,et al. . A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004; 111: 2240– 2245.
    1. Chang YC, Hu DN, Wu WC. . Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmol. 2008; 146: 440– 446.
    1. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H. . Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol. 2006; 142: 883– 885.
    1. Hou H, Huffman K, Rios S, Freeman WR, Sailor MJ, Cheng L. . A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system: pharmacodynamics. Invest Ophthalmol Vis Sci. 2015; 56: 2755– 2763.
    1. Charteris DG. . Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995; 79: 953– 960.
    1. Morescalchi F, Duse S, Gambicorti E, Romano MR, Costagliola C, Semeraro F. . Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid. Mediators Inflamm. 2013; 2013: 269787.
    1. Chiba C. . The retinal pigment epithelium: an important player of retinal disorders and regeneration. Exp Eye Res. 2014; 123: 107– 114.
    1. Nakagawa M, Refojo MF, Marin JF, Doi M, Tolentino FI. . Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1995; 36: 2388– 2395.
    1. Andrews A, Balciunaite E, Leong FL,et al. . Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1999; 40: 2683– 2689.
    1. Radtke ND, Tano Y, Chandler D, Machemer R. . Simulation of massive periretinal proliferation by autotransplantation of retinal pigment epithelial cells in rabbits. Am J Ophthalmol. 1981; 91: 76– 87.
    1. Zhao HM, Sheng MJ, Yu J. . Expression of IGFBP-6 in a proliferative vitreoretinopathy rat model and its effects on retinal pigment epithelial cell proliferation and migration. Int J Ophthalmol. 2014; 7: 27– 33.
    1. Cleary PE, Ryan SJ. . Experimental posterior penetrating eye injury in the rabbit. I. Method of production and natural history. Br J Ophthalmol. 1979; 63: 306– 311.
    1. Fisher SK, Lewis GP. . Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. Vision Res. 2003; 43: 887– 897.
    1. Iandiev I, Uckermann O, Pannicke T,et al. . Glial cell reactivity in a porcine model of retinal detachment. Invest Ophthalmol Vis Sci. 2006; 47: 2161– 2171.
    1. Kirchhof B, Sorgente N. . Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Dev Ophthalmol. 1989; 16: 1– 53.
    1. Nagasaki H, Shinagawa K, Mochizuki M. . Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998; 17: 77– 98.
    1. Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. . TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci. 2000; 41: 2336– 2342.
    1. Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. . Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res. 2014; 40: 16– 34.
    1. Rouberol F, Chiquet C. . Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis [in French]. J Fr Ophtalmol. 2014; 37: 557– 565.
    1. Kim LA, Wong LL, Amarnani DS,et al. . Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy. Mol Vis. 2015; 21: 673– 687.
    1. Wong LL, Lee NG, Amarnani D,et al. . Orbital angiogenesis and lymphangiogenesis in thyroid eye disease: an analysis of vascular growth factors with clinical correlation. Ophthalmology. 2016; 123: 2028– 2036.
    1. Kim LA, Amarnani D, Gnanaguru G, Tseng WA, Vavvas DG, D'Amore PA. . Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms. Invest Ophthalmol Vis Sci. 2014; 55: 4747– 4758.
    1. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. . The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005; 114: 154– 163.
    1. Skalli O, Schurch W, Seemayer T,et al. . Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest. 1989; 60: 275– 285.
    1. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr.. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796– 1808.
    1. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. . Bestrophin, the product of the best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2000; 97: 12758– 12763.
    1. Chu PG, Weiss LM. . Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 2002; 15: 6– 10.
    1. Anlauf E, Derouiche A. . Glutamine synthetase as an astrocytic marker: its cell type and vesicle localization. Front Endocrinol (Lausanne). 2013; 4: 144.
    1. Scholzen T, Gerdes J. . The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182: 311– 322.
    1. Chabner BA, Allegra CJ, Curt GA,et al. . Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985; 76: 907– 912.
    1. Wang YS, Hui YN, Wiedemann P. . Role of apoptosis in the cytotoxic effect mediated by daunorubicin in cultured human retinal pigment epithelial cells. J Ocul Pharmacol Ther. 2002; 18: 377– 387.
    1. Khawly JA, Saloupis P, Hatchell DL, Machemer R. . Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991; 229: 464– 467.
    1. Koutsandrea CN, Miceli MV, Peyman GA, Farahat HG, Niesman MR. . Ciprofloxacin and dexamethasone inhibit the proliferation of human retinal pigment epithelial cells in culture. Curr Eye Res. 1991; 10: 249– 258.
    1. Limb GA, Little BC, Meager A,et al. . Cytokines in proliferative vitreoretinopathy. Eye (Lond). 1991; 5 Pt 6: 686– 693.
    1. Chen XL, Bai YJ, Hu QR, Li SS, Huang LZ, Li XX. . Small interfering RNA targeted to ASPP2 promotes progression of experimental proliferative vitreoretinopathy. Mediators Inflamm. 2016; 2016: 7920631.
    1. Dvashi Z, Goldberg M, Adir O, Shapira M, Pollack A. . TGF-beta1 induced transdifferentiation of rpe cells is mediated by TAK1. PLoS One. 2015; 10: e0122229.
    1. Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR. . In vivo models of proliferative vitreoretinopathy. Nat Protoc. 2007; 2: 67– 77.
    1. Wong CA, Potter MJ, Cui JZ,et al. . Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells. Can J Ophthalmol. 2002; 37: 211– 220.
    1. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. . Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998; 102: 322– 328.
    1. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. . Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxf). 2003; 42: 1189– 1196.
    1. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. . Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 2000; 43: 656– 663.
    1. Seitz M, Zwicker M, Wider B. . Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J Rheumatol. 2001; 28: 496– 501.

Source: PubMed

3
Se inscrever